Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether combined oral contraceptive pill changes adverse effects ‐ Any adverse events compared with levonorgestrel‐releasing intrauterine system (very low certainty).
Combined oral contraceptive pill may leads to lower treatment success (PBAC < 100 at end of treatment or no requirement… compared with levonorgestrel‐releasing intrauterine system (low certainty).
It is very uncertain whether combined oral contraceptive pill changes satisfaction with treatment compared with levonorgestrel‐releasing intrauterine system (very low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (low certainty).
The review found no eligible studies for this question.
Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (moderate certainty).
Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ vomiting compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) may leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (low certainty).
Ulipristal acetate (all doses) leads to lower observed number of pregnancies (all women) compared with levonorgestrel (high certainty).
The review found no eligible studies for this question.
Ulipristal acetate (all doses) showed no clear difference in specific side effects ‐ nausea compared with levonorgestrel (moderate certainty).